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Abstract: In a randomized, double-blind, Phase III study, we compared pasireotide long-acting 
release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing 
carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid 
tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) 
or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on 
frequency of bowel movements and flushing episodes. Objective tumor response was a second-
ary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse 
events were recorded. At the time of a planned interim analysis, the data monitoring committee 
recommended halting the study because of a low predictive probability of showing superior-
ity of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 
octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27–1.97; P=0.53). 
Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds 
ratio, 1.96; 95% CI, 0.89–4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 – not 
reached) with pasireotide versus 6.8 months (5.6 – not reached) with octreotide (hazard ratio, 
0.46; 95% CI, 0.20–0.98; P=0.045). The most frequent drug-related adverse events (pasireotide 
vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea 
(9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available 
somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide 
LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher 
tumor control rate at month 6, although it was statistically not significant, and was associated 
with a longer PFS than octreotide LAR.
Keywords: neuroendocrine tumors, carcinoid syndrome, somatostatin analogues, pasireotide, 
symptom control, progression-free survival
Introduction
Neuroendocrine tumors (NET) are rare and heterogeneous neoplasms arising from the 
diffuse neuroendocrine cell system.1 NET produce and secrete bioactive amines, pep-
tides, and polypeptides.2 Excessive release of bioactive substances, primarily serotonin 
and substance P, is associated with classic carcinoid syndrome in approximately 20% 
of patients with metastatic NET arising from jejunum or ileum (functional NET).3,4 
Clinical manifestations of carcinoid syndrome include episodic flushing, diarrhea, and 
bronchoconstriction; 50%–66% of patients later develop valvular cardiac complica-
tions resulting from higher levels of 5-hydroxyindoleacetic acid and duration of the 
elevated 5-hydroxyindoleacetic acid.3,5,6
correspondence: edward M Wolin
neuroendocrine and gi Oncology Program, 
Markey cancer center, University of Kentucky, 
800 rose street, Ben roach Building, room 450, 
lexington, KY 40536 0093, Usa
Tel +1 859 323 8043
Fax +1 859 257 7715
email edward.wolin@uky.edu 
Journal name: Drug Design, Development and Therapy
Article Designation: Original Research
Year: 2015
Volume: 9
Running head verso: Wolin et al
Running head recto: Pasireotide LAR in NET with carcinoid symptoms
DOI: http://dx.doi.org/10.2147/DDDT.S84177
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5076
Wolin et al
Somatostatin analogues (SSA) remain the gold standard 
treatment for patients with functional NET.5,7 Octreotide 
and lanreotide effectively reduce the frequency of diar-
rhea and flushing in 70%–90% of patients with carcinoid 
symptoms.5,7–9 Loss of symptom response due to tachyphy-
laxis has been reported approximately 6–18 months after 
initiation of treatment.10
Pasireotide (SOM230) is expected to have a distinct 
pharmacodynamic profile given its broader specificity and 
high affinity for somatostatin receptors 1–3 (sst
1–3
) and 
sst
5
 compared with octreotide and lanreotide, which have 
greater specificity for sst
2
.11,12 In a recent Phase II study, 
subcutaneous (SC) pasireotide effectively treated symptoms 
of patients with metastatic functional carcinoid tumors 
resistant to octreotide long-acting repeatable (octreotide 
LAR) therapy.13
Our Phase III study compared the efficacy and safety 
of pasireotide long-acting release (pasireotide LAR) with 
those of octreotide LAR in controlling diarrhea and flushing 
in patients with metastatic NET whose disease-related 
symptoms were inadequately controlled by the highest 
recommended doses of first-generation SSA. A post hoc 
progression-free survival (PFS) analysis was performed 
following the results of objective tumor response.
Methods
study design
This was a multicenter, randomized, blinded, efficacy and 
safety, Phase III study of pasireotide LAR versus octreotide 
LAR in patients with metastatic NET of the digestive 
system who had inadequately controlled carcinoid symp-
toms. Planned enrollment was 216 patients (108 in each 
arm; see the “Sample size and interim analysis” section in 
supplementary materials, Table S1) from 47 centers in 15 
countries (Argentina, Austria, Belgium, Brazil, Canada, 
France, Germany, Italy, Norway, Poland, Singapore, Spain, 
Sweden, UK, and USA) (Figure 1; ClinicalTrials.gov identi-
fier, NCT00690430).
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Figure 1 study design.
Notes: aDiarrhea and/or flushing while receiving maximum approved doses of a currently available SSA for $3 months; bstratification groups (according to inadequately 
controlled baseline symptoms during a 2-week period [14 days] prior to randomization): D + F, mean daily bowel movements of four or more and total flushing episodes of 
five or more; D, mean daily bowel movements of four or more and total flushing episodes of less than five; F, mean daily bowel movements of less than four and total flushing 
episodes of 14 or more; cblinding was not maintained for patients who crossed over to pasireotide lar. D, predominantly diarrhea group; D + F, diarrhea and flushing group; 
F, predominantly flushing group.
Abbreviations: Octreotide lar, octreotide long-acting repeatable; pasireotide lar, pasireotide long-acting release; Ps, performance status; recisT, response evaluation 
criteria in solid Tumors; ssa, somatostatin analogues.
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The study protocol was reviewed by an independent ethics 
committee or institutional review board at each site and met 
the principles of the Declaration of Helsinki. The study was 
monitored by an independent data monitoring committee and 
was overseen by a protocol steering committee. All patients 
provided written informed consent before participation in 
the study.
Patients
Adult patients (age $18 years) with carcinoid tumors of the 
digestive tract were eligible for study enrollment if they had a 
histopathologically confirmed metastatic tumor and one eval-
uable lesion as assessed according to Response Evaluation 
Criteria In Solid Tumors (RECIST; version 1.0).14 For study 
participation, disease progression prior to study entry was not 
mandatory. Other key inclusion criteria included inadequately 
controlled diarrhea and/or flushing (as defined under patient 
screening and treatment) while receiving maximum approved 
doses of the currently available SSA for 3 months prior to 
study entry; Karnofsky performance status $60; and adequate 
bone marrow, renal, and hepatic function. Previous SSA 
doses to establish inadequate control during screening period 
included octreotide LAR 30 mg every 28 days, octreotide SC 
600 μg (total daily dose), lanreotide autogel 120 mg every 
28 days, or lanreotide SR 30 mg every 14 days. Patients with 
impaired fasting glucose or diabetes mellitus were eligible. 
In such patients, HbA
1c
 and fasting glucose were routinely 
measured throughout the study period, additional monitor-
ing was performed, and antidiabetic therapy was started as 
clinically indicated per investigator’s discretion.
Patients were ineligible if they received an SSA at a higher 
than approved dose (except a short-acting formulation) within 
3 months before screening; were receiving radiolabeled SSA 
therapy (within 3 months before recording baseline symp-
toms); received any cytotoxic chemotherapy or interferon 
therapy (within 4 weeks); underwent major surgery (within 
1 month before recording baseline symptoms) or surgical 
therapy of locoregional metastases (within 3 months); under-
went hepatic artery embolization, chemoembolization, or 
radioembolization (yttrium 90 microspheres) within 6 months 
(or 1 month if there were other disease sites) or cryoabla-
tion or radiofrequency ablation of hepatic metastases within 
2 months before recording baseline symptoms; received prior 
therapy with pasireotide; or had diabetes and poorly controlled 
blood glucose levels (glycosylated hemoglobin .8%).
Patient screening and treatment
Inadequate control of carcinoid symptoms was defined as a 
daily mean of four or more bowel movements over a 2-week 
period and five or more flushing episodes during the same 
period within the screening phase. Patients recorded symp-
toms during screening on a touch-tone telephone system.
After screening, eligibility confirmation, and a washout 
period (see the “Washout period” section in supplementary 
materials), patients were randomly assigned 1:1 to receive 
blinded treatment with pasireotide LAR 60 mg or octreotide 
LAR 40 mg. An interactive voice response system was used 
for randomization. True double blinding was not feasible 
due to the different appearances of the LAR formulations. 
Blinding was achieved by an independent nurse who knew 
the treatment assignment (see the “Treatment blinding” sec-
tion in supplementary materials).
Treatments were administered via intragluteal depot 
injections once every 28 days (±3 days) by an independent 
study nurse. For patients who experienced breakthrough 
symptoms after the first injection, SC rescue medication was 
permitted (ie, pasireotide 600 μg bid SC for patients random-
ized to pasireotide LAR and octreotide 100 μg tid SC for 
patients randomized to octreotide LAR). Dose reductions to 
pasireotide LAR 40 mg and octreotide LAR 30 mg for safety 
and tolerability were allowed (see the “Permitted study drug 
adjustments” section in supplementary materials).
The treatment and evaluation periods for the core study 
were 6 months. A blinded treatment extension of up to 
2 years was available in all participating countries except 
the UK. Patients not benefiting from octreotide by the end 
of the 6-month core phase were allowed to switch to pasir-
eotide LAR treatment on entry into the extension phase and 
the blind was broken (see the “Extension study” section in 
supplementary materials).
assessments
Efficacy
The primary efficacy outcome was symptom control (diarrhea 
and/or flushing) based on patient reports of daily frequency 
of bowel movements and flushing episodes. A patient was 
considered to be achieving symptom improvement according 
to the following subgroup-specific criteria (over a 28-day 
period comprising month 6): stratum D, less than four daily 
mean bowel movements and $20% reduction in the daily 
mean number of bowel movements from baseline; stratum 
F, $30% reduction in the total number of flushing episodes 
from baseline; and stratum D + F, less than four mean bowel 
movements, and $20% reduction in the daily mean number 
of bowel movements from baseline plus any reduction in the 
total number of flushing episodes compared with baseline.
Secondary analyses included evaluating the frequency of 
bowel movements alone and the number of flushing episodes 
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alone during month 6 (the last 28 days of treatment) relative 
to the baseline assessment and the objective tumor response 
rate (complete response or partial response) and tumor control 
rate (complete response, partial response, or stable disease) at 
month 6 using RECIST criteria (based on the tumor responses 
assessed by the investigators). Tumors were measured using 
computed tomography or magnetic resonance imaging at 
baseline and every 3 months thereafter.
safety
Safety assessments included monitoring and recording all 
adverse events (AEs) based on the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events, 
version 3.0.15
statistical analysis
The full analysis set consisted of all randomized patients. 
Following the intent-to-treat principle, these patients 
were analyzed according to the treatment assigned at ran-
domization. Demographic and baseline characteristics as 
well as tumor response were evaluated based on the full 
analysis set.
The efficacy analyzable set consisted of the subset of 
full analysis set patients randomized at least 6 months 
before the futility data monitoring committee data cut-
off. It was used to assess primary and secondary efficacy 
outcomes, with the exception of tumor response. A two-
sided Cochran–Mantel–Haenszel test (adjusted for the 
inadequately controlled symptom subgroups; significance 
level, 0.05) compared proportions of patients experiencing 
symptom improvement. Change from baseline in mean 
daily bowel movements and flushing episodes at month 6 
was compared using an analysis of covariance model. 
A two-sided Fisher’s exact test compared objective tumor 
response rate. Odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs) were calculated using logistic 
regression.
The safety analysis set consisted of patients who received 
at least one dose of study drug and had at least one post-
baseline safety assessment, regardless of whether they 
entered the extension phase.
The extension analysis set consisted of patients receiv-
ing at least one dose of study medication in the extension 
phase and was used for safety analyses in the extension 
phase. Patients in the extension analysis set were stratified 
by the treatment received in the extension phase, as follows: 
pasireotide LAR, patients continuing on pasireotide LAR 
in the extension phase; octreotide LAR, patients continuing 
on octreotide LAR in the extension phase; crossover to 
pasireotide LAR, patients receiving octreotide LAR in the 
core phase and pasireotide LAR in the extension phase. 
Patients were excluded if no treatment information was 
available on entry into the extension phase.
An exploratory analysis of PFS was performed to evaluate 
the durability of the tumor response data. Distributions were 
assessed by the Kaplan–Meier method and were compared 
between treatment arms using a two-sided unstratified log-
rank test. Hazard ratio (HR) was estimated with unstratified 
Cox regression.
Results
One hundred ten patients were enrolled between April 2008 
and April 2012, before the study was halted following a 
data monitoring committee recommendation due to a low 
predictive probability of showing superiority of pasireotide 
over octreotide for symptom control (Figure 2). Baseline 
demographic and clinical characteristics of the patients in 
the two treatment arms were similar (Table 1).
Efficacy
Similar proportions of patients receiving pasireotide LAR 
(20.9%) or octreotide LAR (26.7%) achieved symptom 
control at month 6 (OR, 0.73; 95% CI, 0.27–1.97; P=0.53) 
(Table 2). At month 6, the magnitude of reduction in fre-
quency of bowel movements and flushing episodes was 
comparable between treatments (Table S2).
Objective tumor response
At month 6, a higher proportion of patients in the pasireotide 
LAR arm (60.8%) than in the octreotide LAR arm (42.3%) 
achieved stable disease, with a comparable objective 
response rate between arms (2.0% in the pasireotide LAR 
vs 3.8% in the octreotide LAR arm; OR, 0.50; 95% CI, 
0.04–5.69; P=0.57). The tumor control rate at month 6 was 
62.7% with pasireotide LAR and 46.2% with octreotide LAR 
(OR, 1.96; 95% CI, 0.89–4.32; P=0.09). At 48 months, the 
objective tumor response and disease control rates were 
similar between treatment arms (Table S3).
Progression-free survival
In a post hoc analysis, the median PFS based on investigator-
assessed tumor response was 11.8 months (95% CI, 11.0 – 
not reached) in patients receiving pasireotide LAR versus 
6.8 months (95% CI, 5.6 – not reached) in patients receiving 
octreotide LAR (unstratified Cox regression model HR, 0.46; 
95% CI, 0.20–0.98; P=0.045) (Figure 3).
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safety and tolerability
The most common drug-related AEs of any grade among 
patients who received pasireotide LAR were hyperglyce-
mia, fatigue, and nausea (Table 3). The rate of grade 3 or 4 
hyperglycemia was higher with pasireotide LAR (9.4%) than 
with octreotide LAR (1.8%).
AEs leading to treatment discontinuation were more 
frequent with pasireotide LAR (17.0%) than with octreotide 
LAR (7.0%). Two patients receiving pasireotide LAR 
discontinued treatment because of grade 4 hyperglycemia, 
which was manageable with antidiabetic medication. During 
the core phase, AEs leading to study drug discontinuation 
occurred in seven patients (13.2%) in the pasireotide LAR 
arm and were considered study drug related in four patients 
(7.5%): one patient each with diarrhea and flushing, diarrhea 
and bradycardia, hyperglycemia, or liver enzyme elevation. 
In the octreotide LAR arm, no events leading to study dis-
continuation were considered to be drug related. During the 
extension phase, six patients discontinued the study drug due 
to an AE: two patients in the pasireotide LAR arm, one patient 
in the octreotide LAR arm, and three patients in the crossover 
to pasireotide LAR arm. For two patients from the crossover 
arm, the drug-related AEs leading to study discontinuation 
included orthostatic hypotension and dysesthesia and liver 
enzyme elevation.
Serious AEs occurred with comparable frequency in the 
pasireotide LAR (41.5%) and octreotide LAR (36.8%) arms, 
although more serious AEs in the pasireotide LAR arm were 
drug related (17% vs 3.5% with octreotide LAR). Five deaths 
were reported: two in the octreotide LAR arm during the 
core phase due to health deterioration or disease progression 
and three during the extension phase due to disease progres-
sion (pasireotide LAR), hepatic failure (octreotide LAR), 
and carcinoid tumor of the gastrointestinal tract (crossover 
to pasireotide LAR). All deaths were attributed to disease 
progression or underlying malignancy.
Discussion
SSA therapy remains the standard of care for treatment of 
hormonal symptoms in functional NET. Many patients with 
improved carcinoid symptoms experience recurrence and/
or worsening of symptoms despite continued treatment with 
octreotide or lanreotide, and effective management of refrac-
tory carcinoid syndrome remains an unmet medical need.7,16 
110 patients enrolled
53 assigned to receive
pasireotide LAR
(full analysis set)a
35 completed
core phase
21 entered
extension phase
2 completed
extension phase
2 completed
extension phase
1 completed
extension phase
5 discontinued during extension phase
 2 had administrative problemsc
 1 had adverse event
 1 death
 1 had unsatisfactory therapeutic effect
13 discontinued during extension phase
 4 had unsatisfactory therapeutic effect
 4 had administrative problemsc
 2 had adverse events
   2 withdrew consent
 1 death
 
18 discontinued during extension phase
 10 had administrative problems
 3 had unsatisfactory therapeutic effect
 2 had adverse events
 1 had abnormal laboratory values
 1 had abnormal test procedure results
 1 death
23 discontinued during 6-month core phaseb
 10 had unsatisfactory therapeutic effect
 6 had administrative problems
 3 withdrew consent
 2 deaths
 1 abnormal laboratory value
 1 had adverse event
18 discontinued during 6-month core phaseb
 8 had unsatisfactory therapeutic effect
 5 had adverse events
 3 withdrew consent
 1 protocol deviation
 1 drug no longer required
15 crossed over to
pasireotide
6 continued
with octreotide
20 entered
extension phase
34 completed
core phase
57 assigned to receive
octreotide LAR
(full analysis set)a
Figure 2 Patient disposition.
Notes: Demographic and background characteristics. aTwo patients were incorrectly randomized; one patient randomized to the pasireotide lar group actually received 
six injections of octreotide LAR (this patient crossed over to pasireotide LAR in the extension phase and received eight injections of pasireotide LAR), and one patient 
randomized to the octreotide lar group actually received two injections of pasireotide lar; bthree of four patients in the crossover group and one of two patients in the 
octreotide lar group discontinued due to early study termination; cpatients who completed month 6 and did not enter the extension are not counted as discontinuations.
Abbreviations: Octreotide lar, octreotide long-acting repeatable; pasireotide lar, pasireotide long-acting release.
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Although options such as combining interferon-alpha with 
SSA or locoregional treatment (such as hepatic transcatheter 
arterial embolization) could be considered in refractory 
patients, the lack of data from well-controlled studies and 
poor tolerance due to AEs with such therapies substantiate 
the need for new agents. Pasireotide LAR was as effec-
tive as high-dose octreotide LAR in controlling symptoms 
refractory to the highest recommended doses of first-
generation SSA.
It was anticipated that pasireotide LAR would have greater 
efficacy than octreotide LAR due to its broader receptor-
binding profile. During the planned interim futility analysis, 
however, the study showed similar efficacy for symptom con-
trol in an SSA-refractory population despite ~40% of patients 
in each treatment arm discontinuing the study. The higher 
discontinuation rates due to unsatisfactory therapeutic effect, 
15% in the pasireotide LAR arm and 17% in the octreotide 
LAR arm, is not unexpected considering that the study popu-
lation were refractory to SSA therapy for symptom control 
at study entry. In addition, imbalances between treatment 
arms in baseline demographic characteristics (particularly 
proportions of patients with a shorter period since initial 
diagnosis, Karnofsky score, and heterogeneity of primary 
tumor sites) might have confounded results.
Earlier, in an open-label, multicenter, Phase II study, 
Kvols et al13 evaluated pasireotide SC (600–900 μg bid) 
in 45 patients with metastatic NET resistant to octreotide 
LAR. They showed that pasireotide effectively controlled 
carcinoid syndrome symptoms in 27% of patients (symptom 
control for diarrhea and flushing over any consecutive 15-day 
period at a fixed dose of pasireotide, efficacy population).13 
Consistent with these findings, we found that after 6 month’s 
treatment, pasireotide LAR controlled symptoms in 21% of 
patients refractory to octreotide or lanreotide. Collectively, 
the results strongly support pasireotide LAR as an effective 
medical therapy for symptom control in patients with carci-
noid syndrome inadequately controlled by currently available 
SSA. The applicability of the findings to SSA treatment-naive 
patients merits investigation.
SSA have demonstrated antitumor activity in addition to 
their effects on symptom control in patients with functional 
NET. Octreotide is the first SSA shown to have antitumor 
efficacy in a Phase III randomized controlled trial. In the 
PROMID (Placebo-controlled, double-blind, prospective, 
Randomized study on the effect of Octreotide LAR in the 
control of tumor growth in patients with metastatic neuroen-
docrine MIDgut tumors) study, octreotide LAR significantly 
prolonged median time to tumor progression in patients with 
newly diagnosed advanced metastatic midgut NET with or 
Table 1 Demographic and baseline characteristics of the patients
Pasireotide  
LAR n=53
Octreotide 
LAR n=57
Age (years), median (range) 61 (40–80) 63 (28–86)
Sex, n (%)
Male/female 29 (55)/24 (45) 34 (60)/23 (40)
Race, n (%)
caucasian 49 (92) 57 (100)
asian 1 (2) 0
Black 1 (2) 0
Other 2 (4) 0
Karnofsky performance status, n (%)
80–100 49 (93) 50 (88)
,80 3 (6) 6 (11)
Missing 1 (2) 1 (2)
Primary tumor site, n (%)
small intestine 38 (72) 46 (81)
colon 3 (6) 1 (2)
liver 3 (6) 0
Pancreas 1 (2) 1 (2)
lung 0 1 (2)
stomach 0 1 (2)
Othera 8 (15) 7 (12)
Histologic grade of tumor, n (%)
Well differentiated 41 (77) 48 (84)
Moderately differentiated 2 (4) 1 (2)
Unknown 10 (19) 8 (14)
Tumor stage, n (%)
stage i 0 1 (2)
stage ii 0 1 (2)
stage iii 2 (4) 1 (2)
stage iV 46 (87) 47 (83)
Unknown/missing 0/5 (10) 1 (2)/6 (11)
Time since initial diagnosis (years), n (%)
0.5 to ,2 6 (11) 14 (25)
2 to ,5 18 (34) 13 (23)
5 to ,10 11 (21) 18 (32)
$10 7 (13) 7 (12)
Missing 11 (21) 5 (9)
Previous medications, n (%)
chemotherapy 10 (19) 12 (21)
immunotherapy 12 (23) 14 (25)
Targeted therapy 7 (13) 8 (14)
Other 14 (26) 10 (18)
Missing 26 (49) 24 (42)
Previous SSA use, n (%)b
Octreotide lar 45 (85) 50 (88)
Octreotide sc 11 (21) 9 (16)
lanreotide autogel 6 (11) 13 (23)
lanreotide sr 3 (6) 1 (2)
no of patients with baseline 
5-hiaa data
49 49
elevated baseline 5-hiaa  
(.ULN), n (%)
44 (90) 40 (82)
no of patients with  
baseline cga datac
15 17
elevated baseline cga  
(.2× ULN), n (%)
11 (73) 10 (59)
Notes: aOther sites included distal ilium, cecum, gi primary, recto-sigmoid, 
unknown primary, mesentery, appendix, head of pancreas; bpatients might have 
been taking more than 1 ssa prior to study entry; cbaseline cga data were missing 
for approximately 70% of patients as the CgA assessment was introduced with a 
protocol amendment issued after 48 patients had been enrolled.
Abbreviations: cga, chromogranin a; 5-hiaa, 5-hydroxyindoleacetic acid; gi, 
gastrointestinal; octreotide lar, octreotide long-acting repeatable; pasireotide 
lar, pasireotide long-acting release; sc, subcutaneous; sr, sustained release; ssa, 
somatostatin analogues; Uln, upper limit of normal.
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without secretory symptoms (14.3 months vs 6.0 months 
with placebo; HR, 0.34; 95% CI, 0.20–0.59; P=0.000072).17 
In the same study, 66.7% of patients receiving octreotide 
LAR experienced stable disease after 6 months (vs 37.2% 
of those from the placebo arm). Recently, the CLARINET 
study showed that lanreotide improved PFS in patients with 
stable disease gastroenteropancreatic NET versus placebo 
(lanreotide, PFS not reached; placebo, PFS 18 months; HR, 
0.47; 95% CI, 0.30–0.73; P=0.0002).18
This study was designed to evaluate efficacy of pasireotide 
for symptom control, and therefore documentation of disease 
progression prior to study entry was not required. An improved, 
though not statistically significant, tumor control rate at 
6 months for patients receiving pasireotide LAR in our study 
(62.7% vs 46.2% in patients receiving octreotide LAR; OR, 
1.96; 95% CI, 0.89–4.32; P=0.09) drove an exploratory PFS 
analysis. In the post hoc analysis, pasireotide LAR prolonged 
median PFS by 5 months (11.8 months vs 6.8 months with 
octreotide LAR), corresponding to a 54% reduction in esti-
mated risk for disease progression or death (HR, 0.46; 95% CI, 
0.20–0.98; P=0.045). This effect of pasireotide LAR on PFS is 
very encouraging given the refractory population. Data from a 
recent open-label, Phase II study of pasireotide LAR have also 
shown promising antitumor efficacy with PFS of 12.2 months 
(95% CI, 7.7–17.5) in patients with metastatic NET without 
prior systemic therapy, including octreotide or lanreotide.19 
The antitumor activity of pasireotide LAR warrants further 
exploration in a larger study with PFS and additional tumor 
control metrics as predefined end points.
The tumor control rate at 6 months observed in the 
octreotide LAR arm of our study was 46.2%, whereas that 
observed in the PROMID trial was 66.7%.17 Our study is not 
easily comparable with the PROMID study, in which most 
patients were treatment naive, whereas all patients in our 
Table 2 Symptom response: efficacy analyzable seta
Stratum Pasireotide LAR n/N (%) 
 [95% exact CI]
Octreotide LAR n/N (%) 
 [95% exact CI]
Between treatment 
OR [95% CI]
Diarrhea and flushing 5/37 (13.5) [4.5–28.8] 11/39 (28.2) [15.0–44.9] 0.40 [0.12–1.29]
Predominantly diarrhea 2/2 (100) [15.8–100] 1/5 (20.0) [0.5–71.6]
Predominantly flushing 2/4 (50.0) [6.8–93.2] 0/1 (0) [0.0–97.5]
Overall 9/43 (20.9) [10.0–36.0] 12/45 (26.7) [14.6–41.9] 0.73 [0.27–1.97]
P=0.53
Note: aThe efficacy analyzable set consisted of the subset of the full analysis set who were randomized at least 6 months before the futility data monitoring committee data 
cutoff.
Abbreviations: CI, confidence interval; n/N, number of responders/number of patients analyzed; octreotide LAR, octreotide long-acting repeatable; OR, odds ratio; 
pasireotide lar, pasireotide long-acting release.
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study were symptomatic while being treated with the highest 
recommended doses of available SSA.
The safety profiles of pasireotide and octreotide were 
consistent with the known safety profiles of both agents. 
Although the incidence of hyperglycemia was higher in the 
pasireotide LAR arm, it was manageable. One patient dis-
continued due to hyperglycemia suspected to be related to the 
study drug. The increased incidence of hyperglycemia among 
patients receiving pasireotide has been reported.13,19 No cases 
of ketosis or ketoacidosis were observed in this study.
Studies of pasireotide LAR in patients with NET are 
ongoing. The Phase I COOPERATE-1 study has been 
extended to evaluate the long-term safety and tolerability of 
pasireotide LAR combined with everolimus (NCT01590199). 
The randomized, open-label, Phase II COOPERATE-2 study 
will investigate the efficacy of pasireotide LAR plus everoli-
mus in patients with advanced progressive pancreatic NET 
(NCT01374451).
Conclusion
In conclusion, our findings show that pasireotide LAR and 
high-dose octreotide LAR have similar efficacy for symp-
tom control in patients with functional NET and symptoms 
inadequately controlled with the highest recommended doses 
of available SSA. At month 6, a trend toward higher tumor 
control rate was observed with pasireotide LAR, although it 
was statistically not significant. Pasireotide LAR was asso-
ciated with a longer PFS compared with octreotide LAR. 
Safety findings were consistent with known AE profiles for 
both drugs. These results support further investigation of the 
antitumor activity of pasireotide LAR in adequately powered 
prospective Phase III studies and establish its role in tumor 
control for patients with NET.
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Fatigue 6 (11.3) 0 2 (3.5) 1 (1.8) 1 (6.7) 0
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Supplementary materials
sample size and interim analysis
Among patients with inadequately controlled symptoms 
in both diarrhea and flushing (D + F), the response rate for 
octreotide long-acting repeatable (LAR; 40 mg) treatment 
is estimated by medical experts to be ~20%. Given that the 
primary analysis is based on the full analysis set according to 
intent-to-treat principle, the treatment effect may be diluted 
due to early dropouts since early dropouts are considered 
treatment failures. With an estimated 20% dropout rate, the 
response rate based on full analysis set was expected to be 
32% for pasireotide long-acting release (LAR) versus 16% 
for octreotide LAR. The primary efficacy end point was to 
be analyzed using a two-sided Cochran–Mantel–Haenszel 
test adjusting for the inadequately controlled symptom 
subgroups. This allows for detection of an odds ratio of 2.5. 
The estimated patient population from each subgroup is 
listed in Table S1.
A 20% difference was considered clinically meaningful 
to demonstrate the superiority of pasireotide over octreotide 
among this group of patients. With one interim analysis using 
15% predictive power boundary, when 40% of patients com-
plete the study, a sample size of 216 patients (108 patients 
per treatment arm) will be able to detect a common odds ratio 
of 2.5 between pasireotide LAR and octreotide LAR with 
77% power, adjusting for the three inadequately controlled 
symptom groups.
interim analysis
A futility analysis was planned to be performed when 40% of 
patients (approximately 86) completed the month 6 assess-
ment. This included all patients who were randomized at 
least 6 months before the data cutoff date for the futility 
analysis. The primary intent of this futility analysis was to 
assess the risk–benefit ratio and to assess whether the study 
should be stopped in case futility was demonstrated based 
on the primary end point: proportion of patients achieving 
response at month 6. Analysis results were to be reviewed 
by the data monitoring committee, which was then to recom-
mend whether the study should continue. A futility boundary 
defined in terms of predictive power (PP) was used for the 
futility analysis. PP was the probability of rejecting the null 
hypothesis at the final analysis given the data observed at 
the interim. The response rate affects the PP only through its 
prior distribution. For calculating PP, it was assumed that the 
response rate came from a noninformative prior (ie, beta (1, 1) 
distribution), which is equivalent to a prior sample size of 1. 
The futility analysis had the following characteristics:
Table S1 Estimated patient population by inadequately controlled 
symptom subgroup
Subgroup Expected patient  
distribution, %
Response rate, %
Pasireotide LAR Octreotide LAR
D + F 25 32 16
D 50 32 16
F 25 32 16
Notes: D, predominantly diarrhea group; D + F, diarrhea and flushing group; F, 
predominantly flushing group; octreotide LAR, octreotide long-acting repeatable; 
pasireotide lar, pasireotide long-acting release.
Table S2 change in mean daily bowel movements and 
number of flushing episodes at month 6 from baseline: efficacy 
analyzable set
Pasireotide  
LAR n=43
Octreotide  
LAR n=45
Between treatment
LSM (95% CI)
Mean daily bowel movements (mean ± standard deviation)
na 26 32
Baseline 4.9±1.4 6.7±3.3
Month 6 3.5±1.4 4.0±2.3
% change -25.1±24.0 -36.5±29.1 6.9 (-8.0 to 21.9)
Number of flushing episodes per 14-day interval  
(mean ± standard deviation)
na 28 29
Baseline 74.0±50.3 76.6±64.5
Month 6 44.8±43.7 31.1±37.2
% change -42.1±38.8 -49.4±36.7 4.5 (-15.9 to 24.8)
Note: anumber of patients analyzed.
Abbreviations: CI, confidence interval; LSM, least-squares mean; octreotide LAR, 
octreotide long-acting repeatable; pasireotide lar, pasireotide long-acting release.
Table S3 Best overall tumor response rate by investigator 
assessment: full analysis set
Pasireotide  
LAR n=53
Octreotide 
LAR n=57
number of patients analyzed 51 52
Tumor response rate, n (%)
cr 0 0
Pr 1 (2.0) 1 (1.9)
sD 36 (70.6) 38 (73.1)
PD 5 (9.8) 6 (11.5)
UnK 9 (17.6) 7 (13.5)
Response analysis, n (%)
ORR (CR + Pr)  
[95% CI]
1 (2.0)
[0.0–10.4]
1 (1.9)
[0.0–10.3]
OR, 1.02; 95% CI, 0.06–16.76  
P=0.99
Disease control rate (CR +  
Pr + SD) [95% CI]
37 (72.5)
[58.3–84.1]
39 (75.0)
[61.1–86.0]
OR, 0.88; 95% CI, 0.37–2.12  
P=0.78
Abbreviations: CI, confidence interval; CR, complete response; octreotide LAR, 
octreotide long-acting repeatable; Or, odds ratio; Orr, objective response rate; 
pasireotide lar, pasireotide long-acting release; PD, progressive disease; Pr, partial 
response; sD, stable disease; UnK, unknown.
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•	 It was planned to be performed when 40% of patients 
(~86) had had the chance to complete the month 6 
assessment.
•	 It was nonbinding (ie, the P-value of rejecting the null 
hypothesis was not impacted by the futility analysis and 
remained at two-sided 0.05).
•	 Predictive power boundary of 15% was the futility 
boundary.
At interim, if PP was #15%, then the trial could be dis-
continued due to lack of efficacy.
Washout period
For patients on a long-acting somatostatin analogues (SSA), 
symptom recordings started immediately after patients 
received the last dose of SSA and continued for 4 weeks 
(28 days). The last 2-week period (days 15–28) was used to 
assess the frequency of diarrhea and flushing events at base-
line. Use of octreotide subcutaneous (SC) or a short-acting 
antidiarrheal agent was permitted during the first 2 weeks 
(ie, before baseline assessment) as needed for symptom 
control. However, no additional treatment was allowed dur-
ing the last 2-week period (ie, during baseline assessment, 
days 15–28). In addition, patients were to observe an 8-hour 
interval between the last octreotide SC dose or a short-acting 
antidiarrheal agent before the start of the baseline assessment 
period on day 15.
For the patients who were receiving a short-acting SSA 
before study entry, baseline assessment started immediately 
after their enrollment and continued for 2 weeks (14 days). 
These patients continued their prior treatment while baseline 
assessments were being recorded. No other medication to 
control carcinoid symptoms was permitted during baseline 
assessment for these patients.
Treatment blinding
Due to the different appearances of the LAR formulations, a 
true double-blind treatment was not feasible. Blinding was 
achieved by having an independent study nurse/coordinator 
(to whom the treatment assignment was known) administer 
the LAR injections. The patient, investigator, and sponsor 
were blinded to treatment assignment. The independent 
study nurse/coordinator was required to keep the treatment 
information confidential and was instructed not to discuss 
or release information on treatment identities to the patient, 
the investigator, the sponsor’s clinical monitor, or other 
unauthorized personnel. Before study drug administration, 
the independent nurse/coordinator had to document the date 
and time of administration, detach the outer part of the label 
from the packaging, record the patient number on the label, 
and affix it to the source document (drug label form) contain-
ing that patient’s unique patient number. This document was 
kept strictly concealed from the patient, the investigator, and 
the sponsor’s clinical monitor. Immediately after study drug 
administration, the nurse/study coordinator was instructed 
to remove vials, ampules, reconstitution vials, and the outer 
packing and to lock them in a location inaccessible to others. 
In addition, the persons performing the assessments and the 
data analysts were blinded to the identity of the treatment 
from the time of randomization until the study had been 
completed, using the following methods: randomization 
data were kept strictly confidential until the time of unblind-
ing and were not accessible by anyone else involved in the 
treatment; the identity of the LAR intramuscular depot 
treatments was concealed by the independent study nurse, 
who prepared and administered the injections. Investigators 
who wished to continue a patient in the extension-treatment 
period remained blinded if the decision was for the patient to 
continue the same treatment as in the core phase of the study. 
Unblinding was allowed after the patient completed 2 years 
in the extension after all end-of-study assessments had been 
completed and recorded; however, sponsor personnel and 
groups performing central assessments remained blinded 
to treatment until the database was locked. The identity of 
the SC treatments was concealed by the use of study drugs 
that were identical in packaging, labeling and schedule of 
administration, appearance, and odor.
Permitted study drug adjustments
After the first injection, patients who experienced break-
through symptoms were permitted rescue medications as 
needed (ie, pasireotide 600 μg bid SC for patients randomized 
to pasireotide LAR and octreotide 100 μg tid SC for patients 
randomized to octreotide LAR). SC injections were inter-
rupted if they led to tolerability issues but could be resumed 
if needed once the tolerability issue resolved. The pasireotide 
and octreotide rescue medications were supplied in double-
blind packaging and were self-administered by patients. 
Dose reductions to pasireotide LAR 40 mg and octreotide 
LAR 30 mg were permitted to improve tolerability. Patients 
requiring dose reductions returned to the higher dose once 
the tolerability issue resolved.
extension study
The treatment and evaluation period for core study was 
6 months. Patients benefiting from either treatment per 
investigator assessment and not experiencing unacceptable 
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toxicity were permitted to continue the same treatment and 
dose for up to 2 years in the extension phase in a blinded 
manner. Patients not benefiting from pasireotide during the 
core phase were discontinued, and those not benefiting from 
octreotide by the end of the core phase were switched to 
pasireotide LAR treatment on entry into the extension phase 
and the blind was broken. Patients in the extension phase 
recorded their symptoms daily in a paper diary. The treatment 
extension stage was stopped once the patient had achieved 
2 years of the treatment extension or when pasireotide was 
commercially available or the development program was 
discontinued, whichever came first.
